Cargando…

Disentangling the Cost of Orphan Drugs Marketed in the United States

The increasing number and high prices of orphan drugs have triggered concern among patients, payers, and policymakers about the affordability of new drugs approved using the incentives set by the Orphan Drug Act (ODA) of 1983. This study evaluated the factors associated to the differences in the tre...

Descripción completa

Detalles Bibliográficos
Autores principales:	Althobaiti, Hana, Seoane-Vazquez, Enrique, Brown, Lawrence M., Fleming, Marc L., Rodriguez-Monguio, Rosa
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9957503/ https://www.ncbi.nlm.nih.gov/pubmed/36833091 http://dx.doi.org/10.3390/healthcare11040558

Ejemplares similares

Incentives for orphan drug research and development in the United States
por: Seoane-Vazquez, Enrique, et al.
Publicado: (2008)

Fixed-Dose Combination Drug Approvals, Patents and Market Exclusivities Compared to Single Active Ingredient Pharmaceuticals
por: Hao, Jing, et al.
Publicado: (2015)

Ethical imperatives of timely access to orphan drugs: is possible to reconcile economic incentives and patients’ health needs?
por: Rodriguez-Monguio, R., et al.
Publicado: (2017)

Cost-effectiveness analysis of metformin+dipeptidyl peptidase-4 inhibitors compared to metformin+sulfonylureas for treatment of type 2 diabetes
por: Kwon, Christina S., et al.
Publicado: (2018)

Drug utilization and cost in a Medicaid population: A simulation study of community vs. mail order pharmacy
por: Valluri, Satish, et al.
Publicado: (2007)

Changes in the utilization of osteoporosis drugs after the 2010 FDA bisphosphonate drug safety communication
por: Balkhi, Bander, et al.
Publicado: (2018)

Predictors of shortages of opioid analgesics in the US: Are the characteristics of the drug company the missing puzzle piece?
por: Rodriguez-Monguio, Rosa, et al.
Publicado: (2021)

Innovation and competition in advanced therapy medicinal products
por: Seoane‐Vazquez, Enrique, et al.
Publicado: (2019)

Orphans in the Market: The History of Orphan Drug Policy
por: Mikami, Koichi
Publicado: (2019)

A Comparative Assessment of Approvals and Discontinuations of Systemic Antibiotics and Other Therapeutic Areas
por: Rodriguez-Monguio, Rosa, et al.
Publicado: (2023)

Changes in FDA enforcement activities following changes in federal administration: the case of regulatory letters released to pharmaceutical companies
por: Nguyen, Diane, et al.
Publicado: (2013)

Disentangling the causes of mumps reemergence in the United States
por: Gokhale, Deven V., et al.
Publicado: (2023)

Registries for orphan drugs: generating evidence or marketing tools?
por: Hollak, Carla E. M., et al.
Publicado: (2020)

Estimating the clinical cost of drug development for orphan versus non-orphan drugs
por: Jayasundara, Kavisha, et al.
Publicado: (2019)

Patient-reported outcome claims in European and United States orphan drug approvals
por: Jarosławski, Szymon, et al.
Publicado: (2018)

Quantifying the persisting orphan-drug shortage public health crisis in the United States
por: Jarosławski, Szymon, et al.
Publicado: (2016)

Market access of orphan drugs and the role of multi-criteria decision making
por: Simoens, Steven
Publicado: (2012)

The influence of the European paediatric regulation on marketing authorisation of orphan drugs for children
por: Kreeftmeijer-Vegter, Annemarie Rosan, et al.
Publicado: (2014)

Documented Orphaned Oil and Gas Wells Across the United States
por: Boutot, Jade, et al.
Publicado: (2022)

The State’s Duty to the Orphan
por: Spratling, Edgar J.
Publicado: (1902)

Survey of Japanese Orphan Drug Program: Factors Related to Successful Marketing Approval
por: Harada, Kenji, et al.
Publicado: (2019)

Effect of free trade agreements on pharmaceutical market competition: The case of the 2009 US-Peru free trade agreement and its implementation as national drug policy
por: Araujo, Lita, et al.
Publicado: (2021)

Exploratory Analysis of Outpatient Visits for US Adults Diagnosed with Lupus Erythematosus: Findings from the National Ambulatory Medical Care Survey 2006–2016
por: Preciado, Salena Marie, et al.
Publicado: (2022)

New functionalities in Orphanet for orphan drugs, R&D and marketing authorisations to better serve the rare diseases community
por: Hivert, Virginie, et al.
Publicado: (2010)

The Prevalence and Cost of Unapproved Uses of Top-Selling Orphan Drugs
por: Kesselheim, Aaron S., et al.
Publicado: (2012)

Effectiveness, safety and costs of orphan drugs: an evidence-based review
por: Onakpoya, Igho J, et al.
Publicado: (2015)

PIN58 The U.S. International Trade of Medical Products in the COVID-19 Era
por: Preciado, S.M., et al.
Publicado: (2021)

Impact of an Advanced Practice Pharmacist Type 2 Diabetes Management Program: A Pilot Study
por: Lewis, Jelena, et al.
Publicado: (2019)

Assessing the value of orphan drugs using conventional cost-effectiveness analysis: Is it fit for purpose?
por: Postma, Maarten J., et al.
Publicado: (2022)

Cross-national comparative study of orphan drug policies in Saudi Arabia, the United States, and the European Union
por: Balkhi, Bander, et al.
Publicado: (2023)

Orphan Drug Pricing and Costs: A Case Study of Kalydeco and Orkambi
por: Hollis, Aidan
Publicado: (2019)

Does market exclusivity hinder the development of Follow-on Orphan Medicinal Products in Europe?
por: Brabers, Anne EM, et al.
Publicado: (2011)

Dynamics of patents, orphan drug designation, licensing, and revenues from drugs for rare diseases: The market expansion of eculizumab
por: Caetano, Rosângela, et al.
Publicado: (2021)

Healthcare cost of type 1 diabetes mellitus in new-onset children in a hospital compared to an outpatient setting
por: Jasinski, Christopher F, et al.
Publicado: (2013)

Spring migration patterns of red knots in the Southeast United States disentangled using automated telemetry
por: Smith, Adam D., et al.
Publicado: (2023)

Profitability and Market Value of Orphan Drug Companies: A Retrospective, Propensity-Matched Case-Control Study
por: Hughes, Dyfrig A., et al.
Publicado: (2016)

Perspective: Disentangling the effects of tES on neurovascular unit
por: Arora, Yashika, et al.
Publicado: (2023)

Orphan Drugs, Compounded Medication and Pharmaceutical Commons
por: Hendrickx, Kim, et al.
Publicado: (2021)

Orphan medicinal products in Europe and United States to cover needs of patients with rare diseases: an increased common effort is to be foreseen
por: Giannuzzi, Viviana, et al.
Publicado: (2017)

Prescription Drugs Marketed in the United States Should Be Approved by the FDA
por: Shepherd, Marvin
Publicado: (2003)

Cannot write session to /tmp/vufind_sessions/sess_tfmuhjm7q543j9k2rlki0jg48r